PL2531187T3 - Stymulatory sGC lub aktywatory sGC same i w kombinacji z inhibitorami PDE5 do leczenia zwłóknienia wielotorbielowatego - Google Patents

Stymulatory sGC lub aktywatory sGC same i w kombinacji z inhibitorami PDE5 do leczenia zwłóknienia wielotorbielowatego

Info

Publication number
PL2531187T3
PL2531187T3 PL11701683T PL11701683T PL2531187T3 PL 2531187 T3 PL2531187 T3 PL 2531187T3 PL 11701683 T PL11701683 T PL 11701683T PL 11701683 T PL11701683 T PL 11701683T PL 2531187 T3 PL2531187 T3 PL 2531187T3
Authority
PL
Poland
Prior art keywords
sgc
treatment
combination
cystic fibrosis
stimulators
Prior art date
Application number
PL11701683T
Other languages
English (en)
Inventor
Peter Sandner
Degenfeld Georges Von
Johannes-Peter Stasch
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2531187(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of PL2531187T3 publication Critical patent/PL2531187T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL11701683T 2010-02-05 2011-02-03 Stymulatory sGC lub aktywatory sGC same i w kombinacji z inhibitorami PDE5 do leczenia zwłóknienia wielotorbielowatego PL2531187T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10152727 2010-02-05
PCT/EP2011/051532 WO2011095534A1 (en) 2010-02-05 2011-02-03 sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP11701683.2A EP2531187B1 (en) 2010-02-05 2011-02-03 sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS

Publications (1)

Publication Number Publication Date
PL2531187T3 true PL2531187T3 (pl) 2016-01-29

Family

ID=43759663

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11701683T PL2531187T3 (pl) 2010-02-05 2011-02-03 Stymulatory sGC lub aktywatory sGC same i w kombinacji z inhibitorami PDE5 do leczenia zwłóknienia wielotorbielowatego

Country Status (33)

Country Link
US (1) US20130035340A1 (pl)
EP (1) EP2531187B1 (pl)
JP (2) JP6143461B2 (pl)
KR (1) KR101793304B1 (pl)
CN (3) CN107929271A (pl)
AU (1) AU2011212521B2 (pl)
BR (1) BR112012019666A2 (pl)
CA (1) CA2788969C (pl)
CL (1) CL2012002173A1 (pl)
CR (1) CR20120408A (pl)
CY (1) CY1116878T1 (pl)
DK (1) DK2531187T3 (pl)
EA (1) EA025177B1 (pl)
ES (1) ES2548394T3 (pl)
HK (1) HK1212892A1 (pl)
HR (1) HRP20151187T1 (pl)
HU (1) HUE028008T2 (pl)
IL (1) IL221012B (pl)
MA (1) MA33984B1 (pl)
MX (1) MX342944B (pl)
MY (2) MY159697A (pl)
NZ (1) NZ601612A (pl)
PH (1) PH12012501587A1 (pl)
PL (1) PL2531187T3 (pl)
PT (1) PT2531187E (pl)
RS (1) RS54336B1 (pl)
SG (1) SG182819A1 (pl)
SI (1) SI2531187T1 (pl)
SM (1) SMT201500286B (pl)
TN (1) TN2012000397A1 (pl)
UA (1) UA112962C2 (pl)
WO (1) WO2011095534A1 (pl)
ZA (1) ZA201205532B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548394T3 (es) * 2010-02-05 2015-10-16 Adverio Pharma Gmbh Estimuladores de la GCs o activadores de la GCs solos y en combinación con inhibidores de la PDE5 para el tratamiento de la fibrosis quística
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
EP2585055A1 (de) * 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
RS59394B1 (sr) 2012-09-07 2019-11-29 Boehringer Ingelheim Int Alkoksi pirazoli kao rastvorljivi aktivatori guanilatne ciklaze
US10265314B2 (en) * 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
MX2016007522A (es) 2013-12-11 2017-12-15 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
SG10201806565SA (en) 2014-07-22 2018-08-30 Boehringer Ingelheim Int Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
EP3194382B1 (en) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN107406421A (zh) 2014-09-17 2017-11-28 铁木医药有限公司 sGC刺激物
KR20180095594A (ko) 2015-12-18 2018-08-27 노파르티스 아게 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도
AU2017378324B2 (en) 2016-12-16 2021-09-02 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as CFTR potentiators
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
ES2251200T3 (es) * 1998-07-08 2006-04-16 Sanofi-Aventis Deutschland Gmbh N-arilamidas del acido sulfonilaminocarboxilico sustituidas con azufre, su uso y preparaciones farmaceuticas que las comprenden.
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
WO2008138483A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
CN101939053A (zh) * 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
WO2009068652A1 (en) * 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
UY31507A1 (es) 2007-12-03 2009-07-17 Derivados de piridina activadores de guanilato ciclasa soluble
US8461348B2 (en) 2008-04-04 2013-06-11 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
EP2296685B1 (en) * 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2548394T3 (es) * 2010-02-05 2015-10-16 Adverio Pharma Gmbh Estimuladores de la GCs o activadores de la GCs solos y en combinación con inhibidores de la PDE5 para el tratamiento de la fibrosis quística

Also Published As

Publication number Publication date
MX2012009011A (es) 2012-09-07
MA33984B1 (fr) 2013-02-01
MY160856A (en) 2017-03-31
AU2011212521A1 (en) 2012-08-16
HRP20151187T1 (hr) 2015-12-04
DK2531187T3 (en) 2015-11-09
EP2531187A1 (en) 2012-12-12
JP2016155857A (ja) 2016-09-01
US20130035340A1 (en) 2013-02-07
MY159697A (en) 2017-01-13
CY1116878T1 (el) 2017-04-05
CN102770133A (zh) 2012-11-07
SG182819A1 (en) 2012-09-27
CA2788969A1 (en) 2011-08-11
HK1212892A1 (zh) 2016-06-24
RS54336B1 (sr) 2016-02-29
IL221012A0 (en) 2012-09-24
EA201290702A1 (ru) 2013-02-28
CL2012002173A1 (es) 2013-05-17
IL221012B (en) 2018-01-31
EA025177B1 (ru) 2016-11-30
PH12012501587A1 (en) 2020-10-19
CA2788969C (en) 2017-11-21
CR20120408A (es) 2013-02-12
KR101793304B1 (ko) 2017-11-02
BR112012019666A2 (pt) 2017-06-20
SI2531187T1 (sl) 2016-01-29
NZ601612A (en) 2014-08-29
PT2531187E (pt) 2015-10-20
HUE028008T2 (en) 2016-11-28
CN104800219A (zh) 2015-07-29
WO2011095534A1 (en) 2011-08-11
TN2012000397A1 (en) 2014-01-30
ZA201205532B (en) 2014-12-23
EP2531187B1 (en) 2015-08-12
CN107929271A (zh) 2018-04-20
KR20120125276A (ko) 2012-11-14
MX342944B (es) 2016-10-18
ES2548394T3 (es) 2015-10-16
UA112962C2 (uk) 2016-11-25
SMT201500286B (it) 2016-01-08
JP6143461B2 (ja) 2017-06-07
JP6270907B2 (ja) 2018-01-31
AU2011212521B2 (en) 2015-11-19
JP2013518851A (ja) 2013-05-23

Similar Documents

Publication Publication Date Title
PT2531187E (pt) Estimuladores de sgc ou ativadores de sgc sozinhos e em combinação com inibidores de pde5 para o tratamento de fibrose cística (fc)
IL223128A (en) Use of sgc irritants, sgc operators alone and combinations with 5pde inhibitors for the treatment of systemic sclerosis
IL213857A0 (en) Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
ZA201304159B (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
IL214244A0 (en) Scriptaid isosteres and their use in therapy
IL235358B (en) Tritocholine for use in the treatment of cystic fibrosis
IL219768A0 (en) Drug combination with thebromine and its use in therapy
PT2590509T (pt) Método para a preparação e utilização de biocidas enriquecidos em radicais ativos antes da utilização
IL212208A0 (en) Use of ammonium chloride in therapy
IL219769A0 (en) Drug combination with theromine and its use in therapy
ZA201304460B (en) Novel bacterium and extracts of said bacterium and the use of same in therapy
EP2670769A1 (en) R2r1/2 in diagnosis and therapy
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
GB0818663D0 (en) Gene regulation and its use in therapy
EP2934699A4 (en) PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN
GB201000499D0 (en) Treatment of cystic fibrosis
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca
AU2011904834A0 (en) Apricitabine and NRTI combination therapy
AU2012900572A0 (en) Compositions and methods for the treatment of cystic fibrosis
GB201019971D0 (en) Drug composition and its use in therapy
GB201021425D0 (en) Drug composition and its use in therapy
GB201019972D0 (en) Drug composition and its use in therapy
ZA201403477B (en) Apricitabine and pi combination therapy
GB0920267D0 (en) Drug combination and its use in therapy
GB201015789D0 (en) Peptides and their use in the treatment